EP2219629A4 - Novel compounds as cannabinoid receptor ligands - Google Patents

Novel compounds as cannabinoid receptor ligands

Info

Publication number
EP2219629A4
EP2219629A4 EP20080837396 EP08837396A EP2219629A4 EP 2219629 A4 EP2219629 A4 EP 2219629A4 EP 20080837396 EP20080837396 EP 20080837396 EP 08837396 A EP08837396 A EP 08837396A EP 2219629 A4 EP2219629 A4 EP 2219629A4
Authority
EP
European Patent Office
Prior art keywords
novel compounds
receptor ligands
cannabinoid receptor
cannabinoid
ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20080837396
Other languages
German (de)
French (fr)
Other versions
EP2219629A1 (en
Inventor
William A Carroll
Sridhar Peddi
Arturo Perez-Medrano
Michael J Dart
Derek W Nelson
Tongmei Li
Bo Liu
Teodozyj Kolasa
Jennifer Frost
Xueqing Wang
Steven P Latshaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of EP2219629A1 publication Critical patent/EP2219629A1/en
Publication of EP2219629A4 publication Critical patent/EP2219629A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EP20080837396 2007-10-12 2008-10-08 Novel compounds as cannabinoid receptor ligands Withdrawn EP2219629A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97965307P 2007-10-12 2007-10-12
US12/246,808 US9193713B2 (en) 2007-10-12 2008-10-07 Compounds as cannabinoid receptor ligands
PCT/US2008/079182 WO2009048936A1 (en) 2007-10-12 2008-10-08 Novel compounds as cannabinoid receptor ligands

Publications (2)

Publication Number Publication Date
EP2219629A1 EP2219629A1 (en) 2010-08-25
EP2219629A4 true EP2219629A4 (en) 2012-02-29

Family

ID=40549525

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20080837396 Withdrawn EP2219629A4 (en) 2007-10-12 2008-10-08 Novel compounds as cannabinoid receptor ligands

Country Status (7)

Country Link
US (1) US9193713B2 (en)
EP (1) EP2219629A4 (en)
JP (1) JP2011500579A (en)
CN (1) CN101820868A (en)
CA (1) CA2700049A1 (en)
TW (1) TW200932222A (en)
WO (1) WO2009048936A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140385A2 (en) 2006-05-31 2007-12-06 Abbott Laboratories Thiazole compounds as cannabinoid receptor ligands and uses thereof
US8841334B2 (en) * 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
CA2647598A1 (en) * 2006-05-31 2007-12-06 Abbott Laboratories Compounds as cannabinoid receptor ligands and uses thereof
CN101765594A (en) 2007-03-28 2010-06-30 雅培制药有限公司 1,3-thiazoles-2 (3H)-ylidene compounds as cannabinoid receptor ligand
US7872033B2 (en) * 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2008144360A1 (en) * 2007-05-18 2008-11-27 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
MX2010010023A (en) 2008-03-11 2010-11-30 Abbott Lab Novel compounds as cannabinoid receptor ligands.
US8846730B2 (en) * 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
CN102216277A (en) 2008-09-16 2011-10-12 雅培制药有限公司 Novel compounds as cannabinoid receptor ligands
PA8854001A1 (en) * 2008-12-16 2010-07-27 Abbott Lab NEW COMPOUNDS AS CANABINOID RECEIVERS LIGANDS
EP2411382A1 (en) 2009-03-27 2012-02-01 Abbott Laboratories Compounds as cannabinoid receptor ligands
JP6404357B2 (en) 2013-09-19 2018-10-10 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ N-Acylimino Heterocyclic Compound
EP3046916A1 (en) * 2013-09-19 2016-07-27 Basf Se N-acrylimino heterocyclic compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2254339A1 (en) * 1973-12-14 1975-07-11 Shionogi & Co
JPS57171986A (en) * 1981-04-14 1982-10-22 Taiho Yakuhin Kogyo Kk Heterocylic ring compound containing sulfur
EP0639569A1 (en) * 1991-03-11 1995-02-22 Nippon Soda Co., Ltd. Novel heterocyclic compound
EP1300401A1 (en) * 2000-06-30 2003-04-09 Sumitomo Pharmaceuticals Company, Limited Five-membered-ring compound
EP1640369A1 (en) * 2003-06-27 2006-03-29 Dainippon Sumitomo Pharma Co., Ltd. Thiazolimine compound and oxazolimine compound
EP1820504A1 (en) * 2004-11-15 2007-08-22 Taisho Pharmaceutical Co., Ltd Imine compound

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1522361A1 (en) 1966-03-08 1969-07-24 Agfa Gevaert Ag Sensitization of photosensitive polymers
US3557142A (en) * 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
DE1772867A1 (en) 1968-07-15 1971-06-16 Agfa Gevaert Ag Sensitization of layers made of photo-crosslinkable polymers
DE3333450A1 (en) * 1983-09-16 1985-04-11 Hoechst Ag, 6230 Frankfurt CARBONYL METHYLENE HETEROCYCLES CONTAINING TRIHALOGEN METHYL GROUPS, METHOD FOR THE PRODUCTION THEREOF AND LIGHT-SENSITIVE MIXTURE THAT CONTAINS THESE COMPOUNDS
US4978664A (en) * 1984-08-06 1990-12-18 Sterling Drug Inc. 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indole pharmaceutical compositions
US4885295A (en) * 1984-08-06 1989-12-05 Sterling Drug Inc. Method of use of 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indoles
DE3533331A1 (en) 1985-09-18 1987-03-26 Heumann Ludwig & Co Gmbh Pyridothiazole derivatives, process for their preparation, and medicaments containing these compounds
DE3807381A1 (en) * 1988-03-07 1989-09-21 Hoechst Ag HETEROCYCLIC COMPOUNDS CONTAINING 4,6-BIS-TRICHLOROMETHYL-S-TRIAZIN-2-YL-GROUPS, PROCESS FOR THE PREPARATION THEREOF AND LIGHT-SENSITIVE MIXTURE CONTAINING THIS COMPOUND
TW205041B (en) 1989-08-07 1993-05-01 Fujisawa Pharmaceutical Co
DE4021439A1 (en) * 1989-12-14 1991-06-20 Bayer Ag 2-iminopyridine DERIVATIVES
US6559186B1 (en) * 1990-02-26 2003-05-06 Arc 1, Inc. Compositions and methods of treatment of sympathetically maintained pain
US4973587A (en) * 1990-03-08 1990-11-27 Sterling Drug Inc. 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method
US5013837A (en) * 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
DE69325018T2 (en) 1992-03-03 1999-09-16 Idemitsu Kosan Co PYRAZOLE DERIVATIVES
EP0568096B1 (en) 1992-04-30 1998-07-29 Hodogaya Chemical Co., Ltd. Benzothiazole derivative and agricultural and horticultural fingicide composition containing the same
US5654322A (en) * 1992-08-11 1997-08-05 Wakunaga Seiyaku Kabushiki Kaisha Biphenylmethane derivatives and pharmaceuticals containing the same
WO1994022821A1 (en) * 1993-04-05 1994-10-13 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives as testosterone 5 alpha-reductase inhibitors
US5395836A (en) 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
JPH06345736A (en) 1993-06-14 1994-12-20 Tokuyama Soda Co Ltd Production of urethane compound
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
CA2189573A1 (en) 1994-05-17 1995-11-23 Ronald E. Hackler N-(5-isothiazolyl)amide pesticides
ES2185707T5 (en) 1994-07-08 2007-05-01 Ev3 Inc. INTRAVASCULAR FILTRATION DEVICE.
FR2735774B1 (en) 1995-06-21 1997-09-12 Sanofi Sa USE OF HUMAN CB2 RECEPTOR AGONIST COMPOUNDS FOR THE PREPARATION OF IMMUNOMODULATORY DRUGS, NOVEL CB2 RECEPTOR AGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6277985B1 (en) 1995-09-15 2001-08-21 Pharmacia & Upjohn Company Aminoaryl oxazolidinone N-oxides
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
US6323214B1 (en) * 1997-10-29 2001-11-27 Medco Research, Inc Allosteric adenosine receptor modulators
US6358992B1 (en) * 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
IL145962A0 (en) 1999-04-20 2002-07-25 Syngenta Ltd Pesticidal indazole or benzotriazole derivatives
DE19928033A1 (en) 1999-06-18 2000-12-21 Basf Ag Use of cyclic enamines as light stabilizers
FR2796643B1 (en) 1999-07-22 2005-04-29 Sod Conseils Rech Applic 2-ARYLIMINO-2,3-DIHYDROTHIAZOLES DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USE
GB9918037D0 (en) * 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
WO2001016138A1 (en) 1999-08-27 2001-03-08 Abbott Laboratories Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors
CA2384757A1 (en) 1999-09-14 2001-03-22 Shionogi & Co., Ltd. 2-imino-1,3-thiazine derivatives
WO2001028557A1 (en) 1999-10-18 2001-04-26 University Of Connecticut Cannabimimetic indole derivatives
US7741365B2 (en) 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
IL132661A (en) 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for the peripheral cannabinoid receptor
GB0002032D0 (en) 2000-01-28 2000-03-22 Zeneca Ltd Chemical compounds
GB0002034D0 (en) 2000-01-28 2000-03-22 Zeneca Ltd Chemical compounds
US6653304B2 (en) 2000-02-11 2003-11-25 Bristol-Myers Squibb Co. Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
GB0006289D0 (en) * 2000-03-15 2000-05-03 Smithkline Beecham Plc New use
GB0010437D0 (en) 2000-04-28 2000-06-14 Darwin Discovery Ltd Process
US6369052B1 (en) * 2000-08-07 2002-04-09 Georgetown University Combination of huperzine and nicotinic compounds as a neuroprotective agent
FR2816938B1 (en) * 2000-11-22 2003-01-03 Sanofi Synthelabo 3-AROYLINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US7173027B2 (en) 2001-01-29 2007-02-06 University Of Connecticut Receptor selective cannabimimetic aminoalkylindoles
AU2002310441A1 (en) 2001-06-14 2003-01-02 The Regents Of The University Of California A novel signaling pathway for the production of inflammatory pain and neuropathy
US7949668B2 (en) * 2001-08-20 2011-05-24 Pardalis, Inc. Common point authoring system for the complex sharing of hierarchically authored data objects in a distribution chain
WO2003029199A1 (en) 2001-09-28 2003-04-10 Takeda Chemical Industries, Ltd. Benzene derivatives, process for preparing the same and use thereof
AU2002363174B2 (en) * 2001-11-01 2008-09-25 Janssen Pharmaceutica N.V. Amide derivatives as glycogen synthase kinase 3-beta inhibitors
US6727247B2 (en) 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
WO2003097605A1 (en) * 2002-05-16 2003-11-27 Bayer Cropscience Gmbh Pesticidal pyridinecarboxamide derivatives
JP3902523B2 (en) * 2002-08-05 2007-04-11 富士フイルム株式会社 Optical information recording medium and information recording method
US20040077617A1 (en) * 2002-10-22 2004-04-22 Bennani Youssef L. Fused cycloalkyl amides and acids and their therapeutic applications
FR2847899B1 (en) 2002-11-29 2006-04-28 Sanofi Synthelabo Indole-3-carboxamide derivatives, preparation and application in therapy
US7390670B2 (en) * 2003-02-20 2008-06-24 Lumigen, Inc. Signalling compounds and methods for detecting hydrogen peroxide
US20040259887A1 (en) 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
WO2005021547A2 (en) * 2003-08-28 2005-03-10 Pharmaxis Pty Ltd. Heterocyclic cannabinoid cb2 receptor antagonists
EP1670804A2 (en) 2003-09-10 2006-06-21 GPC Biotech AG Heterobicyclic compounds as pharmaceutically active agents
AU2004299198A1 (en) 2003-12-08 2005-06-30 F. Hoffmann-La Roche Ag Novel thiazole derivates
GB0402357D0 (en) 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
US7307163B2 (en) 2004-04-19 2007-12-11 Symed Labs Limited Process for the preparation of linezolid and related compounds
SE0401345D0 (en) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
SE0401342D0 (en) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds
EP1768967B1 (en) 2004-07-20 2009-04-22 Symed Labs Limited Novel intermediates for linezolid and related compounds
US7511013B2 (en) * 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
EP1833824B1 (en) * 2004-12-21 2016-08-03 AbbVie Inc. 3-cycloalkylcarbonyl indoles as cannabinoid receptor ligands
FR2880023B1 (en) 2004-12-23 2007-02-23 Sanofi Aventis Sa N - [(4,5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL] AMINE DERIVATIVES AND THEIR PREPARATION AND THERAPEUTIC USE
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
TW200700387A (en) 2005-03-21 2007-01-01 Akzo Nobel Nv 1-benzylindole-2-carboxamide derivatives
US7674912B2 (en) * 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
US20070155738A1 (en) * 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
TW200716636A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US7514068B2 (en) * 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
WO2007046550A1 (en) * 2005-10-21 2007-04-26 Mitsubishi Tanabe Pharma Corporation Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity
TW200804338A (en) 2005-11-24 2008-01-16 Astrazeneca Ab New compounds
CA2647598A1 (en) 2006-05-31 2007-12-06 Abbott Laboratories Compounds as cannabinoid receptor ligands and uses thereof
US8841334B2 (en) * 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
WO2007140385A2 (en) * 2006-05-31 2007-12-06 Abbott Laboratories Thiazole compounds as cannabinoid receptor ligands and uses thereof
TW200813000A (en) * 2006-06-27 2008-03-16 Abbott Lab Thiazoline and oxazoline derivatives and their methods of use
EP2054393A1 (en) * 2006-07-28 2009-05-06 Synthon B.V. Crystalline erlotinib
US7985768B2 (en) * 2006-08-31 2011-07-26 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2008028093A1 (en) * 2006-08-31 2008-03-06 Abbott Laboratories Compounds as cb2 cannabinoid receptor ligands
WO2008063781A2 (en) 2006-10-12 2008-05-29 Abbott Laboratories Chemical compounds as cannabinoid receptor ligands
US8796267B2 (en) * 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
US9763894B2 (en) * 2006-12-05 2017-09-19 Virginia Commonwealth University Inflammation therapy
TW200831092A (en) * 2006-12-21 2008-08-01 Astrazeneca Ab Therapeutic agents
WO2008079687A1 (en) 2006-12-22 2008-07-03 Abbott Laboratories Novel compounds as cannabinoid receptor ligands and uses thereof
KR101222412B1 (en) * 2007-02-15 2013-01-15 에프. 호프만-라 로슈 아게 2-aminooxazolines as taar1 ligands
CN101765594A (en) * 2007-03-28 2010-06-30 雅培制药有限公司 1,3-thiazoles-2 (3H)-ylidene compounds as cannabinoid receptor ligand
US8501794B2 (en) * 2007-04-17 2013-08-06 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7872033B2 (en) 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
KR20100012031A (en) * 2007-04-19 2010-02-04 콘서트 파마슈티컬즈, 인크. Deuterated morpholinyl compounds
WO2008144360A1 (en) 2007-05-18 2008-11-27 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
US7531685B2 (en) * 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US20090131485A1 (en) * 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) * 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
WO2009045476A1 (en) * 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
US20090105338A1 (en) * 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
EP2212298B1 (en) * 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
US8044071B2 (en) * 2007-10-18 2011-10-25 Abbott Laboratories Method for reducing side effects of CB2 receptor agonist therapy using a combination of a selective CB2 receptor agonist and a selective CB1 receptor antagonist
CA2703591C (en) * 2007-10-26 2013-05-07 Concert Pharmaceuticals, Inc. Deuterated darunavir
CA2706586A1 (en) 2007-11-21 2009-05-28 Alan S. Florjancic Novel compounds as cannabinoid receptor ligands and uses thereof
MX2010010023A (en) * 2008-03-11 2010-11-30 Abbott Lab Novel compounds as cannabinoid receptor ligands.
MX2011001755A (en) * 2008-08-15 2011-03-24 Abbott Lab Imine derivatives as cannabinoid receptor ligands.
US8846730B2 (en) * 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
CN102216277A (en) * 2008-09-16 2011-10-12 雅培制药有限公司 Novel compounds as cannabinoid receptor ligands
CA2741047A1 (en) 2008-11-04 2010-05-14 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
PA8854001A1 (en) 2008-12-16 2010-07-27 Abbott Lab NEW COMPOUNDS AS CANABINOID RECEIVERS LIGANDS
ES2542234T3 (en) 2009-03-27 2015-08-03 Abbvie Inc. Compounds as cannabinoid receptor ligands
WO2010111573A1 (en) 2009-03-27 2010-09-30 Abbott Laboratories Compounds as cannabinoid receptor ligands
EP2411382A1 (en) * 2009-03-27 2012-02-01 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2011159785A1 (en) * 2010-06-15 2011-12-22 Abbott Laboratories Novel compounds as cannabinoid receptor ligands

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2254339A1 (en) * 1973-12-14 1975-07-11 Shionogi & Co
JPS57171986A (en) * 1981-04-14 1982-10-22 Taiho Yakuhin Kogyo Kk Heterocylic ring compound containing sulfur
EP0639569A1 (en) * 1991-03-11 1995-02-22 Nippon Soda Co., Ltd. Novel heterocyclic compound
EP1300401A1 (en) * 2000-06-30 2003-04-09 Sumitomo Pharmaceuticals Company, Limited Five-membered-ring compound
EP1640369A1 (en) * 2003-06-27 2006-03-29 Dainippon Sumitomo Pharma Co., Ltd. Thiazolimine compound and oxazolimine compound
EP1820504A1 (en) * 2004-11-15 2007-08-22 Taisho Pharmaceutical Co., Ltd Imine compound

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SCHUART, J. ET AL: "2-Aminooxazole and 2-iminooxazoline. 3. Chosen examples of the homologous series of 3-substituted-2-imino-4-methyl-5- phenyloxazoline", XP002667122, retrieved from STN Database accession no. 1974:403802 *
OHTA ET AL: "N-Alkylidenearylcarboxamides as new potent and selective CB2 cannabinoid receptor agonists with good oral bioavailability", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 17, no. 22, 7 September 2007 (2007-09-07), pages 6299 - 6304, XP022297147, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2007.09.004 *
See also references of WO2009048936A1 *
VASIL'EVA V F ET AL: "Synthesis and properties of 2-imino-3-benzyl-5-phenyl-1,3,4-oxadiazoline", CAPLUS, 1970, XP002996394 *

Also Published As

Publication number Publication date
US20090105306A1 (en) 2009-04-23
JP2011500579A (en) 2011-01-06
EP2219629A1 (en) 2010-08-25
US9193713B2 (en) 2015-11-24
TW200932222A (en) 2009-08-01
WO2009048936A1 (en) 2009-04-16
CA2700049A1 (en) 2009-04-16
CN101820868A (en) 2010-09-01

Similar Documents

Publication Publication Date Title
EP2219629A4 (en) Novel compounds as cannabinoid receptor ligands
EP2222165A4 (en) Novel compounds as cannabinoid receptor ligands and uses thereof
GB0710528D0 (en) Novel compounds
EP2152081A4 (en) Novel compounds
EP2146745A4 (en) Novel compounds
ZA201101590B (en) Substituted benzamides as cannabinoid receptor ligands
GB0705882D0 (en) Novel compounds
GB0706630D0 (en) Novel compounds
IL200801A0 (en) Pyrimidinyl-piperazines useful as d3/d2 receptor ligands
GB0705803D0 (en) Novel compounds
GB0710863D0 (en) Novel compounds
GB0708858D0 (en) Novel compounds
GB0703973D0 (en) Novel compounds
GB0714245D0 (en) novel estrogwen receptor ligands
GB0707721D0 (en) Novel estrogen receptor ligands
GB0706636D0 (en) Receptor ligands
GB0724430D0 (en) Receptor ligands
GB0708747D0 (en) Novel compounds
GB0706501D0 (en) Novel compounds
GB0709461D0 (en) Novel compounds
GB0700993D0 (en) Novel compounds
GB0700991D0 (en) Novel compounds
GB0710217D0 (en) Novel compounds
GB0708223D0 (en) Novel compounds
GB0708222D0 (en) Novel compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100511

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 413/14 20060101ALI20120118BHEP

Ipc: A61K 31/42 20060101ALI20120118BHEP

Ipc: A61P 43/00 20060101ALI20120118BHEP

Ipc: A61K 31/015 20060101AFI20120118BHEP

Ipc: C07D 417/06 20060101ALI20120118BHEP

Ipc: A61P 9/00 20060101ALI20120118BHEP

Ipc: C07D 417/14 20060101ALI20120118BHEP

Ipc: A61K 31/422 20060101ALI20120118BHEP

Ipc: C07D 405/06 20060101ALI20120118BHEP

Ipc: A61K 31/433 20060101ALI20120118BHEP

Ipc: A61P 37/00 20060101ALI20120118BHEP

Ipc: A61P 11/00 20060101ALI20120118BHEP

Ipc: A61P 25/28 20060101ALI20120118BHEP

Ipc: C07D 413/06 20060101ALI20120118BHEP

Ipc: A61P 29/00 20060101ALI20120118BHEP

Ipc: A61K 31/341 20060101ALI20120118BHEP

Ipc: A61P 25/04 20060101ALI20120118BHEP

Ipc: A61K 31/4155 20060101ALI20120118BHEP

Ipc: A61K 31/351 20060101ALI20120118BHEP

Ipc: A61P 35/00 20060101ALI20120118BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20120201

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABBVIE INC.

17Q First examination report despatched

Effective date: 20160208

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160819